Actively Recruiting
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-25
100
Participants Needed
1
Research Sites
574 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.
CONDITIONS
Official Title
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically diagnosed stage IIIB or IV non-small cell lung cancer
- Experienced failure or recurrence after first-line standard treatment
- At least one measurable tumor lesion
- No anti-cancer treatment within four weeks before enrolling
- Any gender, aged 18 years or older
- ECOG performance status of 0 to 2
- Expected survival of at least 6 months
- Sufficient organ function based on blood and biochemical tests
- Female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception until six months after therapy
- Voluntary participation with signed informed consent and good compliance for follow-up
You will not qualify if you...
- Having two or more types of tumors
- Active viral or bacterial infection not controlled by treatment
- Positive for HIV, syphilis, or uncontrolled hepatitis B or C infections
- Active rheumatic diseases, organ transplantation, or severe immune system disorders
- Severe heart or lung dysfunction
- Severe chronic diseases affecting kidney, liver, or other major organs
- Any other serious illness that may interfere with treatment or follow-up, including neurological, psychiatric, immunoregulatory, metabolic, or infectious diseases
- Participation in other drug or biological therapy clinical trials currently or within 30 days prior
- Need for long-term immunosuppressive drug use or treatment for autoimmune diseases
- Need for long-term glucocorticoid use
- Women who are pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
zhang Zhenfeng
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
Z
zhang zhenfeng, MD,PHD
CONTACT
C
CHEN deji, MD,PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here